Skip to content

ROLE OF AYURVEDIC TREATMENT IN MACULAR DEGENERATION IN OLD AGE PATIENT

a randomized control clinical study to evaluate the effect of nripvallabha ghrita nasya and rasayan ghan vati in the management of pitta vidagdha drishti w.s.r. to armd (dry type) â??

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/052006
Enrollment
30
Registered
2023-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H353- Degeneration of macula and posterior pole

Interventions

Intervention1: Nasya Procedure with Nripvallabha Ghrita and Rasayan Ghan Vati: 1.Nasya-Patients will be advised not to take food before Nasya, mild massage on neck, face, and forehead will be done fol

Sponsors

NATIONAL INSTITUTE OF AYURVEDA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients between age of 40 to 70 years. 2.Patients presenting with classical sign and symptoms of Pitta Vidagdha Drishti & Early to intermediate form of Dry ARMD (i.e, presence of drusens or pigmentary changes around the macula).

Exclusion criteria

Exclusion criteria: 1.Presence of any other retinal or macular pathology other than Non-Exudative ARMD such as Exudative ARMD, Diabetic retinopathy, Central geographic atrophy, Haemorrhagic condition of fundus or retinal fluid. 2.History of retinal laser or surgical therapy in study eye. 3.Contraindication of pupil dilatation in the study eye. 4.Mature cataract or media opacification in either eye which limits an adequate view of fundus. 5.Unable to maintain stable fixation for OCT imagining. 6.Patient having systemic problem:- Disorders other than ocular conditions such as Hypertensive patients with systolic BP >180 and diastolic BP >100 mm Hg, FBS (fasting blood sugar) level > 120 mg/dl & PPBS( Post prandial Blood sugar) > 200 mg/dl, severe cardiac diseases, and deranged lipid profile.

Design outcomes

Primary

MeasureTime frame
CHANGES IN NUMBER AND SIZE OF DRUSENS AND THICKNEES IN MACULATimepoint: 45 DAYS

Secondary

MeasureTime frame
Changes in visual acuity Change in colour vision Change in Amsler grid test findings (metamorphopsia) Changes in fundus examination Timepoint: 45 Days

Countries

India

Contacts

Public ContactDr Anil Kumar

NATIONAL INSTITUTE OF AYURVEDA

vaidya.rajsoni@gmail.com9455067007

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026